Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.3 USD | -0.56% | -1.48% | +22.63% |
Sales 2024 * | 22.15M 27.77M 2.22B | Sales 2025 * | 36.37M 45.59M 3.64B | Capitalization | 800M 1B 79.95B |
---|---|---|---|---|---|
Net income 2024 * | -42M -52.65M -4.2B | Net income 2025 * | -72M -90.26M -7.2B | EV / Sales 2024 * | 32 x |
Net cash position 2024 * | 91.29M 114M 9.13B | Net cash position 2025 * | 82.95M 104M 8.29B | EV / Sales 2025 * | 19.7 x |
P/E ratio 2024 * |
-45.8
x | P/E ratio 2025 * |
-32.9
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Silence Therapeutics plc
1 day | -0.56% | ||
1 week | -1.48% | ||
Current month | -2.56% | ||
1 month | +0.28% | ||
3 months | -4.40% | ||
6 months | +131.52% | ||
Current year | +22.63% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Tooman
CEO | Chief Executive Officer | 58 | 05/01/21 |
Director of Finance/CFO | 52 | 31/03/21 | |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Romano
CTO | Chief Tech/Sci/R&D Officer | 64 | 28/07/19 |
David Lemus
BRD | Director/Board Member | 61 | 20/06/18 |
Iain Ross
CHM | Chairman | 71 | 01/07/04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
02/05/24 | 21.3 | -0.56% | 67 563 |
01/05/24 | 21.42 | -2.01% | 86,828 |
30/04/24 | 21.86 | -0.09% | 209,747 |
29/04/24 | 21.88 | +1.27% | 203,860 |
26/04/24 | 21.6 | -0.07% | 125,885 |
Delayed Quote Nasdaq, May 02, 2024 at 09:00 pm
More quotesEPS Revisions
- Stock Market
- Equities
- SLN Stock